Evidence map›Paper›PMID 38065965›Full record

ArticleScientific reports2023

Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry.

Loukia G Karacosta, Danny Pancirer, Jordan S Preiss, Jalen A Benson, Winston Trope, Joseph B Shrager, Arthur Wai Sung, Joel W Neal, Sean C Bendall, Heather Wakelee and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2025
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Loukia G KaracostaDepartment of Biomedical Data Science, Stanford University, Stanford, CA, 94305, USA.
Danny PancirerStanford Cancer Institute - Clinical Trials Office, Stanford University, Stanford, CA, 94305, USA.
Jordan S PreissStanford Cancer Institute - Clinical Trials Office, Stanford University, Stanford, CA, 94305, USA.
Jalen A BensonDepartment of Cardiothoracic Surgery, Stanford University, Stanford, CA, 94305, USA.
Winston TropeDepartment of Cardiothoracic Surgery, Stanford University, Stanford, CA, 94305, USA.
Joseph B ShragerDepartment of Cardiothoracic Surgery, Stanford University, Stanford, CA, 94305, USA.
Arthur Wai SungDivision of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA, 94305, USA.
Joel W NealDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, 94305, USA.
Sean C BendallDepartment of Pathology, Stanford University, Stanford, CA, 94305, USA.
Heather WakeleeDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, 94305, USA.
Sylvia K PlevritisDepartment of Biomedical Data Science, Stanford University, Stanford, CA, 94305, USA. sylvia.plevritis@stanford.edu.
Stanford University · US

Funding

Spatial-Genomic Integrative Multi-Species Analysis of Lymph Node MetastasisU54CA209971 · NCI · STANFORD UNIVERSITY · PI NOLAN, GARRY P, PLEVRITIS, SYLVIA KATINA · 2016 to 2021
$11.0M
Systems Biology of Tumor-Immune-Stromal Interactions in Metastatic ProgressionU54CA274511 · NCI · STANFORD UNIVERSITY · PI EDGAR G. ENGLEMAN, SYLVIA KATINA PLEVRITIS · 2023 to 2026
$9.5M
Cancer Systems Biology Scholars ProgramR25CA180993 · NCI · STANFORD UNIVERSITY · PI PLEVRITIS, SYLVIA KATINA · 2014 to 2018
$2.2M
NCI NIH HHS R25 CA180993NCI NIH HHS U54 CA209971NCI NIH HHS U54 CA274511
6 · The paper itself

Abstract

Malignant pleural effusions (MPEs) can be utilized as liquid biopsy for phenotyping malignant cells and for precision immunotherapy, yet MPEs are inadequately studied at the single-cell proteomic level. Here we leverage mass cytometry to interrogate immune and epithelial cellular profiles of primary tumors and pleural effusions (PEs) from early and late-stage non-small cell lung cancer (NSCLC) patients, with the goal of assessing epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) states in patient specimens. By using the EMT-MET reference map PHENOSTAMP, we observe a variety of EMT states in cytokeratin positive (CK+) cells, and report for the first time MET-enriched CK+ cells in MPEs. We show that these states may be relevant to disease stage and therapy response. Furthermore, we found that the fraction of CD33+ myeloid cells in PEs was positively correlated to the fraction of CK+ cells. Longitudinal analysis of MPEs drawn 2 months apart from a patient undergoing therapy, revealed that CK+ cells acquired heterogeneous EMT features during treatment. We present this work as a feasibility study that justifies deeper characterization of EMT and MET states in malignant cells found in PEs as a promising clinical platform to better evaluate disease progression and treatment response at a personalized level.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPleural EffusionPleural Effusion, MalignantEpithelial-Mesenchymal TransitionHumansLiquid BiopsyProteomics

Identifiers

PMID38065965
PMCPMC10709404
OpenAlexW4389475870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.